This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Flublok® Influenza Vaccine Availability Update: Product To Be Available To Allow Vaccination By Thanksgiving

MERIDEN, Conn., Oct. 10, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that they expect the first doses of Flublok influenza vaccine for the 2013/2014 season to be released in time for vaccinations to occur prior to Thanksgiving. 

According to the Centers for Disease Control and Prevention (CDC), influenza activity typically peaks in January or later.  It takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, so it is best that people get vaccinated before then.

FFF Enterprises is the exclusive distributor of Flublok.  To ensure an adequate supply and timely delivery of Flublok, vaccinators should place their orders with FFF as soon as possible.  Orders can be placed by calling (800) 843-7477 or online at www.MyFluVaccine.com.

Manon Cox, President and CEO of Protein Sciences said, "We are pleased to announce the timing of Flublok availability."  She added, "It is important for people to know that the vaccine is coming and will be available in time for people to get protected for the season."

About Protein Sciences and Flublok

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals.  

On January 16, 2013, the U.S. FDA approved Flublok influenza vaccine, coined revolutionary because it is made by making just the active ingredient needed for protection without growing influenza virus.  Flublok is made in a 100% egg-free system using modern cell culture technology.  Flublok is highly pure and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, antibiotics or latex.  In addition, it contains 3x the active ingredient in traditional flu vaccines.  The CDC recommends the use of Flublok for all adults 18-49 years old and specifically for those in that age range that have a known or suspected egg allergy, regardless of severity.

Learn more at www.proteinsciences.com and www.Flublok.com.

Important Safety Information Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.Flublok should not be administered to anyone with a severe allergic reaction (e.g., anaphylaxis) to any vaccine component. Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) within 6 weeks of receipt of a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your healthcare professional immediately. Vaccination with Flublok may not protect all individuals. Please see the complete  Package Insert available at www.Flublok.com or call 203-686-0800 for more information.

SOURCE Protein Sciences Corporation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs